Trial Profile
A Prospective, Multicenter, Randomized, Open-label, Active Controlled, Two-parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib at 7.5 mg/kg/Day to Dacarbazine in the Treatment of Patients With Non-resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-kit
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Masitinib (Primary) ; Dacarbazine
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Sponsors AB Science
- 02 Dec 2019 Status changed from active, no longer recruiting to discontinued.
- 02 Aug 2019 Primary endpoint (Objective Response Rate) has been met, according to the AB Science media release.
- 02 Aug 2019 Results presented in the AB Science media release.